Insider Selling: Enfusion, Inc. (NYSE:ENFN) Insider Sells 2,064 Shares of Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) insider Bronwen Bastone sold 2,064 shares of Enfusion stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $23,694.72. Following the sale, the insider now owns 225,001 shares of the company's stock, valued at approximately $2,583,011.48. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Bronwen Bastone also recently made the following trade(s):

• On Wednesday, March 5th, Bronwen Bastone sold 3,126 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $35,573.88.
• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $8,195.17.

Enfusion Stock Performance

ENFN traded down $0.06 on Friday, hitting $11.24. The company had a trading volume of 970,369 shares, compared to its average volume of 1,164,913. The stock has a fifty day moving average price of $10.98 and a 200-day moving average price of $9.89. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million during the quarter, compared to analysts' expectations of $53.98 million. Analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Enfusion

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock valued at $9,770,000 after purchasing an additional 70,367 shares during the last quarter. Wellington Management Group LLP grew its stake in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock valued at $1,974,000 after purchasing an additional 178,821 shares during the last quarter. Barclays PLC grew its stake in shares of Enfusion by 251.4% during the third quarter. Barclays PLC now owns 86,039 shares of the company's stock worth $817,000 after acquiring an additional 61,554 shares during the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of Enfusion during the third quarter worth about $867,000. Hedge funds and other institutional investors own 81.05% of the company's stock.

Analyst Ratings Changes

ENFN has been the subject of several research analyst reports. Piper Sandler lifted their target price on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Finally, William Blair restated a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $11.13.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.